Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Alternative CD44 splicing in intestinal stem cells and tumorigenesis

Oncogene volume 33, pages 537–538 (2014)Cite this article

Subjects

Abstract

As an important player in stem cells and cancer, CD44 is expressed in multiple isoforms via alternative mRNA splicing. Whether, and if so, how various isoforms play distinct roles in normal stem cells and tumorigenesis remains unclear. In this issue of Oncogene, Zeilstra et al. report studies showing that intestinal stem cells express a specific CD44 variant that promotes intestinal tumorigenesis induced by the activation of Wnt signaling, whereas the more commonly expressed standard CD44 isoform is not expressed by stem cells and does not promote tumor formation. This finding demonstrates an isoform-specific function of CD44 in intestinal stem cells and tumorigenesis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Gunthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13–24.

    Article  CAS  Google Scholar 

  2. Ponta H, Sherman L, Herrlich PA . CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33–45.

    Article  CAS  Google Scholar 

  3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983–3988.

    Article  CAS  Google Scholar 

  4. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158–10163.

    Article  CAS  Google Scholar 

  5. Zoller M . CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254–267.

    Article  Google Scholar 

  6. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134: 62–73.

    Article  CAS  Google Scholar 

  7. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211–215.

    Article  CAS  Google Scholar 

  8. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE . Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167–1174.

    Article  Google Scholar 

  9. Krause DS, Lazarides K, von Andrian UH, Van Etten RA . Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006; 12: 1175–1180.

    Article  CAS  Google Scholar 

  10. Katayama Y, Hidalgo A, Chang J, Peired A, Frenette PS . CD44 is a physiological E-selectin ligand on neutrophils. J Exp Med 2005; 201: 1183–1189.

    Article  CAS  Google Scholar 

  11. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST . Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008; 68: 3655–3661.

    Article  CAS  Google Scholar 

  12. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003–1007.

    Article  CAS  Google Scholar 

  13. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608–611.

    Article  CAS  Google Scholar 

  14. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064–1074.

    Article  CAS  Google Scholar 

  15. Warzecha CC, Carstens RP . Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 2012; 22: 417–427.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biology, Albert Einstein College of Medicine, Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine, Bronx, NY, USA

    W Guo & P S Frenette

Authors
  1. W Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P S Frenette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W Guo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guo, W., Frenette, P. Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 33, 537–538 (2014). https://doi.org/10.1038/onc.2013.260

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.260

This article is cited by

Search

Advanced search

Quick links